Kuhn Theresa M, Ahmad Sarfraz, Recio Fernando O, Awada Ahmad, McKenzie Nathalie D, Kendrick James E, Keller Andrew, Holloway Robert W
Gynecologic Oncology, AdventHealth Cancer Institute, Orlando, Florida, USA
Gynecologic Oncology, AdventHealth Cancer Institute, Orlando, Florida, USA.
Int J Gynecol Cancer. 2024 Jul 1;34(7):977-984. doi: 10.1136/ijgc-2024-005402.
External beam radiation with sensitizing platinum is the recommended therapy for locally advanced vulvar cancers not amenable to curative surgery and is associated with considerable acute and chronic side effects. Radical vulvectomy post-radiation for persistent disease is often compromised with poor wound healing. We describe clinical outcomes for patients who received neoadjuvant chemotherapy plus bevacizumab followed by radical vulvectomy for locally advanced vulvar cancer.
We performed retrospective analyses of all patients at our institution who underwent radical vulvectomy from January 2015 to November 2023. Of 113 patients, 13 patients underwent neoadjuvant chemotherapy. Demographics and clinicopathologic data were extracted, and descriptive statistical analyses were performed. Cases with neoadjuvant chemotherapy plus bevacizumab were further evaluated for response, adverse effects, and survival.
Neoadjuvant chemotherapy was administered to 13 patients with stage II-IV disease that involved the urethra, vagina, or anus. Lesion sizes ranged from 4 to 20 cm (median 7 cm). Patients received 2-6 cycles of carboplatin or cisplatin, paclitaxel, and bevacizumab. Nine (69.2%) patients had partial pathologic responses, and four patients had complete responses. All patients had negative surgical margins. Ten (76.9%) patients had radiographic evidence of inguinal lymph node metastasis prior to neoadjuvant chemotherapy, and four had residual nodal disease. Only one patient developed a superficial groin seroma. Three patients developed recurrence, two locally and one distant, and there was one death. The median follow-up was 23 months (range 6-84 months).
Neoadjuvant chemotherapy using combination platinum/paclitaxel/bevacizumab was efficacious for locally advanced vulvar cancer, resulting in complete resections, negative margins, and excellent wound healing. A multi-institutional phase II trial is warranted to validate these findings.
对于无法进行根治性手术的局部晚期外阴癌,推荐使用铂类增敏的外照射放疗,但其会带来相当多的急慢性副作用。放疗后因疾病持续而进行的根治性外阴切除术常因伤口愈合不良而受到影响。我们描述了接受新辅助化疗加贝伐单抗后行根治性外阴切除术治疗局部晚期外阴癌患者的临床结局。
我们对2015年1月至2023年11月在本机构接受根治性外阴切除术的所有患者进行了回顾性分析。113例患者中,13例接受了新辅助化疗。提取人口统计学和临床病理数据,并进行描述性统计分析。对接受新辅助化疗加贝伐单抗的病例进一步评估反应、不良反应和生存率。
13例II-IV期累及尿道、阴道或肛门的患者接受了新辅助化疗。病变大小为4至20厘米(中位值7厘米)。患者接受了2-6周期的卡铂或顺铂、紫杉醇和贝伐单抗治疗。9例(69.2%)患者有部分病理反应,4例患者有完全反应。所有患者手术切缘均为阴性。10例(76.9%)患者在新辅助化疗前有腹股沟淋巴结转移的影像学证据,4例有残留淋巴结疾病。仅1例患者出现浅表腹股沟血清肿。3例患者出现复发,2例为局部复发,1例为远处复发,1例死亡。中位随访时间为23个月(范围6-84个月)。
铂类/紫杉醇/贝伐单抗联合新辅助化疗对局部晚期外阴癌有效,可实现完整切除、切缘阴性且伤口愈合良好。有必要开展多机构II期试验来验证这些发现。